Farhan Nashid, Dahal Upendra P, Wahlstrom Jan
Pharmacokinetics and Drug Metabolism, Amgen Inc., South San Francisco, California, USA.
Pharmacokinetics and Drug Metabolism, Amgen Inc., Thousand Oaks, California, USA.
J Clin Pharmacol. 2024 Oct;64(10):1222-1235. doi: 10.1002/jcph.2484. Epub 2024 Jun 19.
Uridine 5'-diphospho-glucuronosyltransferases (UGTs) demonstrate variable expression in the pediatric population. Thus, understanding of age-dependent maturation of UGTs is critical for accurate pediatric pharmacokinetics (PK) prediction of drugs that are susceptible for glucuronidation. Ontogeny functions of major UGTs have been previously developed and reported. However, those ontogeny functions are based on in vitro data (i.e., enzyme abundance, in vitro substrate activity, and so on) and therefore, may not translate to in vivo maturation of UGTs in the clinical setting. This report describes meta-analysis of the literature to develop and compare ontogeny functions for 8 primary UGTs (UGT1A1, UGT1A4, UGT1A6, UGT1A9, UGT2B7, UGT2B10, UGT2B15, and UGT2B17) based on published in vitro and in vivo studies. Once integrated with physiologically based pharmacokinetics modeling models, in vivo activity-based ontogeny functions demonstrated somewhat greater prediction accuracy (mean squared error, MSE: 0.05) compared to in vitro activity (MSE: 0.104) and in vitro abundance-based ontogeny functions (MSE: 0.129).
尿苷5'-二磷酸葡萄糖醛酸基转移酶(UGTs)在儿科人群中表现出不同的表达。因此,了解UGTs的年龄依赖性成熟对于准确预测易发生葡萄糖醛酸化的药物的儿科药代动力学(PK)至关重要。主要UGTs的个体发育功能此前已得到开发和报道。然而,这些个体发育功能基于体外数据(即酶丰度、体外底物活性等),因此,可能无法转化为临床环境中UGTs的体内成熟情况。本报告描述了对文献的荟萃分析,以基于已发表的体外和体内研究,开发并比较8种主要UGTs(UGT1A1、UGT1A4、UGT1A6、UGT1A9、UGT2B7、UGT2B10、UGT2B15和UGT2B17)的个体发育功能。一旦与基于生理的药代动力学建模模型相结合,基于体内活性的个体发育功能与基于体外活性(均方误差,MSE:0.104)和基于体外丰度的个体发育功能(MSE:0.129)相比,显示出更高的预测准确性(均方误差,MSE:0.05)。